Cardiovascular Systems Inc. (CSI) featured two-year data from its ORBIT II study of the company’s Diamondback 360 coronary orbital atherectomy system (OAS) in a late-breaking presentation at the 2015 Society for Cardiovascular Angiography and Interventions (SCAI) conference. Diamondback 360 is a U.S. Food and Drug Administration (FDA)-approved atherectomy technology indicated for the treatment of severely calcified lesions.
